Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor - PubMed (original) (raw)
Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor
Lois Witters et al. Cancer Res. 2008.
Abstract
The ErbB family of receptors is overexpressed in numerous human tumors. Overexpression correlates with poor prognosis and resistance to therapy. Use of ErbB-specific antibodies to the receptors (Herceptin or Erbitux) or ErbB-specific small-molecule inhibitors of the receptor tyrosine kinase activity (Iressa or Tarceva) has shown clinical efficacy in several solid tumors. An alternative method of affecting ErbB-initiated tumor growth and survival is to block sheddase activity. Sheddase activity is responsible for cleavage of multiple ErbB ligands and receptors, a necessary step in availability of the soluble, active form of the ligand and a constitutively activated ligand-independent receptor. This sheddase activity is attributed to the ADAM (a disintegrin and metalloprotease) family of proteins. ADAM 10 is the main sheddase of epidermal growth factor (EGF) and HER-2/neu cleavage, whereas ADAM17 is required for cleavage of additional EGF receptor (EGFR) ligands (transforming growth factor-alpha, amphiregulin, heregulin, heparin binding EGF-like ligand). This study has shown that addition of INCB3619, a potent inhibitor of ADAM10 and ADAM17, reduces in vitro HER-2/neu and amphiregulin shedding, confirming that it interferes with both HER-2/neu and EGFR ligand cleavage. Combining INCB3619 with a lapatinib-like dual inhibitor of EGFR and HER-2/neu kinases resulted in synergistic growth inhibition in MCF-7 and HER-2/neu-transfected MCF-7 human breast cancer cells. Combining the INCB7839 second-generation sheddase inhibitor with lapatinib prevented the growth of HER-2/neu-positive BT474-SC1 human breast cancer xenografts in vivo. These results suggest that there may be an additional clinical benefit of combining agents that target the ErbB pathways at multiple points.
Similar articles
- Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Witters LM, Witkoski A, Planas-Silva MD, Berger M, Viallet J, Lipton A. Witters LM, et al. Oncol Rep. 2007 Feb;17(2):465-9. Oncol Rep. 2007. PMID: 17203189 - Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R. Massarweh S, et al. Cancer Res. 2006 Aug 15;66(16):8266-73. doi: 10.1158/0008-5472.CAN-05-4045. Cancer Res. 2006. PMID: 16912207 - Basic science of HER-2/neu: a review.
Hung MC, Lau YK. Hung MC, et al. Semin Oncol. 1999 Aug;26(4 Suppl 12):51-9. Semin Oncol. 1999. PMID: 10482194 Review. - Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors.
Sanderson MP, Dempsey PJ, Dunbar AJ. Sanderson MP, et al. Growth Factors. 2006 Jun;24(2):121-36. doi: 10.1080/08977190600634373. Growth Factors. 2006. PMID: 16801132 Review.
Cited by
- Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance.
Chen C, Zhao F, Peng J, Zhao D, Xu L, Li H, Ma S, Peng X, Sheng X, Sun Y, Wang T, Dong H, Ding Y, Wu Z, Liang X, Gao L, Wang H, Ma C, Li C. Chen C, et al. Cell Rep Med. 2024 Aug 20;5(8):101686. doi: 10.1016/j.xcrm.2024.101686. Cell Rep Med. 2024. PMID: 39168104 Free PMC article. - Soluble receptors in cancer: mechanisms, clinical significance, and therapeutic strategies.
Park EJ, Lee CW. Park EJ, et al. Exp Mol Med. 2024 Feb;56(1):100-109. doi: 10.1038/s12276-023-01150-6. Epub 2024 Jan 5. Exp Mol Med. 2024. PMID: 38182653 Free PMC article. Review. - Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next?
Tannoury M, Garnier D, Susin SA, Bauvois B. Tannoury M, et al. Cancers (Basel). 2022 Dec 7;14(24):6026. doi: 10.3390/cancers14246026. Cancers (Basel). 2022. PMID: 36551511 Free PMC article. Review. - GW-2974 and SCH-442416 modulators of tyrosine kinase and adenosine receptors can also stabilize human telomeric G-quadruplex DNA.
Salem AA, El Haty IA, Ghattas MA. Salem AA, et al. PLoS One. 2022 Dec 7;17(12):e0277963. doi: 10.1371/journal.pone.0277963. eCollection 2022. PLoS One. 2022. PMID: 36476719 Free PMC article. - Immunomodulatory role of metalloproteinase ADAM17 in tumor development.
Wang K, Xuan Z, Liu X, Zheng M, Yang C, Wang H. Wang K, et al. Front Immunol. 2022 Nov 17;13:1059376. doi: 10.3389/fimmu.2022.1059376. eCollection 2022. Front Immunol. 2022. PMID: 36466812 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous